Crescent Reports Q4 Revenue of $10.8M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy CBIO?
Reports Q4 revenue $10.8M vs .$0 last year. "2025 was a transformational year for Crescent and our efforts to deliver next generation therapies that can improve outcomes for people living with cancer. We expanded our pipeline and accelerated our efforts to deliver best-in-class novel combinations through our exciting partnership with Kelun-Biotech," said Joshua Brumm, chief executive officer of Crescent. "We now have our Phase 1/2 ASCEND clinical trial underway for CR-001, which is positioned to be an immuno-oncology backbone in the treatment of solid tumors. Three more trials are on track to initiate this year, including the first Phase 1/2 ADC combination trial with CR-001. We are rapidly advancing toward multiple clinical data readouts beginning in the first quarter of 2027 and with our recent private placement, we are well funded to deliver on these milestones."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CBIO
Wall Street analysts forecast CBIO stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 18.760
Low
22.00
Averages
28.20
High
35.00
Current: 18.760
Low
22.00
Averages
28.20
High
35.00
About CBIO
Crescent Biopharma, Inc. is a biotechnology company. The Company is focused on advancing the next wave of therapies for cancer patients. The Company’s pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Crescent Biopharma Announces Upcoming Investor Conferences
- Investor Conference Schedule: Crescent Biopharma is set to participate in several investor conferences in May 2026, including the BofA Securities Healthcare Conference on May 13, the Stifel Virtual Targeted Oncology Forum on May 20, and the TD Cowen 7th Annual Oncology Innovation Summit on May 26, showcasing its advancements in cancer treatment.
- Live Webcast Availability: Each presentation will be available via live webcast on Crescent's investor website, with replays accessible for 90 days post-event, ensuring investors can stay updated on the company's latest developments and strategic direction.
- Clinical Pipeline Overview: Crescent's clinical pipeline features its lead program, a PD-1 x VEGF bispecific antibody, along with novel antibody-drug conjugates (ADCs), aiming to rapidly advance potentially transformative therapies for various solid tumors through multiple treatment modalities.
- Company Vision: Crescent Biopharma envisions becoming a world-leading oncology company focused on delivering the next wave of therapies for cancer patients, reflecting its innovation and market potential in the biopharmaceutical sector.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma's Board approved the grant of 12,525 stock options to two non-executive employees on April 23, 2026, as equity inducement awards under the 2025 Employment Inducement Incentive Award Plan, highlighting the company's commitment to attracting talent.
- Option Terms: The options have an exercise price of $25.70 per share and a 10-year term, designed to incentivize employees for long-term service and foster innovation in cancer treatment.
- Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service and enhancing employee loyalty and motivation.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, to rapidly develop potentially transformative treatments for various solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On March 26, 2026, Crescent Biopharma approved the grant of a total of 35,325 stock options to three non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent.
- Option Terms: The options have an exercise price of $13.50 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and one-forty-eighth vesting monthly thereafter, ensuring continuous service from employees.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in attracting high-quality talent.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, developing various potentially transformative therapies, including a PD-1 x VEGF bispecific antibody, to address a range of solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Options Granted: Crescent Biopharma's Board approved the grant of 45,675 stock options to two non-executive employees on March 5, 2026, as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness in cancer treatment.
- Option Details: The options have an exercise price of $11.33 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and one-forty-eighth vesting monthly thereafter, ensuring continuous service to realize the incentive's benefits.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring that the company adheres to regulations while attracting talent, thereby enhancing investor confidence.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, to provide potentially transformative treatment options for cancer patients and strengthen its market position.
See More
Crescent Biopharma Partners with Kelun-Biotech to Expand Oncology Pipeline
- Strategic Partnership: Crescent has established a collaboration with Sichuan Kelun-Biotech to develop CR-001 (a PD-1 x VEGF bispecific antibody) and multiple antibody-drug conjugates (ADCs), which is expected to accelerate the expansion of its oncology pipeline and significantly enhance market competitiveness.
- Clinical Trial Progress: The ASCEND global clinical trial has commenced to evaluate CR-001's efficacy in various advanced solid tumors, with preliminary clinical data expected to be reported in Q1 2027, further validating its potential as an immuno-oncology backbone.
- Funding Support: Crescent completed a $185 million private placement, providing financial backing for key clinical data readouts and ensuring operational funding through 2028, thereby strengthening its R&D capabilities in cancer treatment.
- Increased R&D Spending: Research and development expenses reached $138.1 million in 2025, a significant increase from 2024, reflecting the company's ongoing investment in projects like CR-001 and CR-002, aimed at rapidly advancing innovative therapies.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma approved the grant of 24,600 stock options to two non-executive employees on February 17, 2026, as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness in cancer treatment.
- Option Details: The granted options have a 10-year term with an exercise price of $9.33 per share, complying with Nasdaq listing rules, ensuring that employees receive attractive economic incentives upon accepting employment, thereby promoting stability within the company.
- Vesting Arrangement: Each employee's options will vest one-fourth on the first anniversary of their start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service with Crescent to receive long-term incentives, thus enhancing employee loyalty and motivation.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing various innovative therapies, including a PD-1 x VEGF bispecific antibody, with the goal of rapidly developing potentially transformative treatments for a range of solid tumors.
See More
Crescent Biopharma Announces Upcoming Investor Conferences
- Investor Conference Schedule: Crescent Biopharma is set to participate in several investor conferences in May 2026, including the BofA Securities Healthcare Conference on May 13, the Stifel Virtual Targeted Oncology Forum on May 20, and the TD Cowen 7th Annual Oncology Innovation Summit on May 26, showcasing its advancements in cancer treatment.
- Live Webcast Availability: Each presentation will be available via live webcast on Crescent's investor website, with replays accessible for 90 days post-event, ensuring investors can stay updated on the company's latest developments and strategic direction.
- Clinical Pipeline Overview: Crescent's clinical pipeline features its lead program, a PD-1 x VEGF bispecific antibody, along with novel antibody-drug conjugates (ADCs), aiming to rapidly advance potentially transformative therapies for various solid tumors through multiple treatment modalities.
- Company Vision: Crescent Biopharma envisions becoming a world-leading oncology company focused on delivering the next wave of therapies for cancer patients, reflecting its innovation and market potential in the biopharmaceutical sector.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma's Board approved the grant of 12,525 stock options to two non-executive employees on April 23, 2026, as equity inducement awards under the 2025 Employment Inducement Incentive Award Plan, highlighting the company's commitment to attracting talent.
- Option Terms: The options have an exercise price of $25.70 per share and a 10-year term, designed to incentivize employees for long-term service and foster innovation in cancer treatment.
- Vesting Schedule: Options will vest one-fourth on the first anniversary of the employee's start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service and enhancing employee loyalty and motivation.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, to rapidly develop potentially transformative treatments for various solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: On March 26, 2026, Crescent Biopharma approved the grant of a total of 35,325 stock options to three non-executive employees as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent.
- Option Terms: The options have an exercise price of $13.50 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and one-forty-eighth vesting monthly thereafter, ensuring continuous service from employees.
- Compliance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to compliance and transparency in attracting high-quality talent.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, developing various potentially transformative therapies, including a PD-1 x VEGF bispecific antibody, to address a range of solid tumors.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Options Granted: Crescent Biopharma's Board approved the grant of 45,675 stock options to two non-executive employees on March 5, 2026, as part of the 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness in cancer treatment.
- Option Details: The options have an exercise price of $11.33 per share and a 10-year term, with one-fourth vesting on the first anniversary of employment and one-forty-eighth vesting monthly thereafter, ensuring continuous service to realize the incentive's benefits.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), ensuring that the company adheres to regulations while attracting talent, thereby enhancing investor confidence.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing innovative therapies including a PD-1 x VEGF bispecific antibody, to provide potentially transformative treatment options for cancer patients and strengthen its market position.
See More
Crescent Biopharma Partners with Kelun-Biotech to Expand Oncology Pipeline
- Strategic Partnership: Crescent has established a collaboration with Sichuan Kelun-Biotech to develop CR-001 (a PD-1 x VEGF bispecific antibody) and multiple antibody-drug conjugates (ADCs), which is expected to accelerate the expansion of its oncology pipeline and significantly enhance market competitiveness.
- Clinical Trial Progress: The ASCEND global clinical trial has commenced to evaluate CR-001's efficacy in various advanced solid tumors, with preliminary clinical data expected to be reported in Q1 2027, further validating its potential as an immuno-oncology backbone.
- Funding Support: Crescent completed a $185 million private placement, providing financial backing for key clinical data readouts and ensuring operational funding through 2028, thereby strengthening its R&D capabilities in cancer treatment.
- Increased R&D Spending: Research and development expenses reached $138.1 million in 2025, a significant increase from 2024, reflecting the company's ongoing investment in projects like CR-001 and CR-002, aimed at rapidly advancing innovative therapies.
See More
Crescent Biopharma Grants Stock Options to Employees
- Stock Option Grant: Crescent Biopharma approved the grant of 24,600 stock options to two non-executive employees on February 17, 2026, as part of its 2025 Employment Inducement Incentive Award Plan, aimed at attracting and retaining talent to enhance the company's competitiveness in cancer treatment.
- Option Details: The granted options have a 10-year term with an exercise price of $9.33 per share, complying with Nasdaq listing rules, ensuring that employees receive attractive economic incentives upon accepting employment, thereby promoting stability within the company.
- Vesting Arrangement: Each employee's options will vest one-fourth on the first anniversary of their start date, with one-forty-eighth vesting monthly thereafter, ensuring continuous service with Crescent to receive long-term incentives, thus enhancing employee loyalty and motivation.
- Company Vision: Crescent Biopharma aims to become a world-leading oncology company, advancing various innovative therapies, including a PD-1 x VEGF bispecific antibody, with the goal of rapidly developing potentially transformative treatments for a range of solid tumors.
See More
